Questran and Interstitial lung disease - a phase IV clinical study of FDA data

Summary:

Interstitial lung disease is reported as a side effect among people who take Questran (cholestyramine), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Arava, and have Rheumatoid arthritis.

The phase IV clinical study analyzes which people have Interstitial lung disease when taking Questran. It is created by eHealthMe based on reports of 4,400 people who have side effects when taking Questran from the FDA, and is updated regularly.

What is Questran?

Questran has active ingredients of cholestyramine. It is often used in diarrhea. eHealthMe is studying from 4,490 Questran users. Check the latest studies of Questran.

What is Interstitial lung disease?

Interstitial lung disease is found to be associated with 1,500 drugs and 1,839 conditions by eHealthMe. Check the latest studies of Interstitial lung disease.

On Jul, 08, 2026

4,400 people reported to have side effects when taking Questran.
Among them, 21 people (0.48%) have Interstitial lung disease.

Could Questran cause Interstitial lung disease?

Among these 21 people:

How long have people been on Questran when they have Interstitial lung disease? *

What is the gender of people who have Interstitial lung disease when taking Questran? *

female: 50 %
male: 50 %

What is the age of people who have Interstitial lung disease when taking Questran? *

What are other drugs people take besides Questran? *

What are other side effects people have besides Interstitial lung disease? *

Dyspnea (difficult or laboured breathing): 6 people, 28.57%
Eosinophilic Pneumonia (eosinophil accumulates in the lung): 5 people, 23.81%
Joint Pain: 5 people, 23.81%
Nausea (feeling of having an urge to vomit): 4 people, 19.05%
Chest Pain: 4 people, 19.05%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 4 people, 19.05%
Fever: 4 people, 19.05%
Haemoglobin Decreased: 4 people, 19.05%
Fatigue (feeling of tiredness): 3 people, 14.29%
Pneumonia Mycoplasmal (mycoplasma pneumonia (mp) is a contagious respiratory infection): 3 people, 14.29%

What are the existing conditions these people have? *

Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 7 people, 33.33%
High Blood Cholesterol: 4 people, 19.05%
Osteoporosis (bones weak and more likely to break): 4 people, 19.05%
High Blood Pressure: 3 people, 14.29%
Pain: 3 people, 14.29%
Pleural Mesothelioma Malignant (cancer of the pleura, or the membrane that lines the lungs): 3 people, 14.29%
Skin Infection: 2 people, 9.52%
Gastritis Erosive (a break in the surface layer of the membrane lining the stomach with infection): 2 people, 9.52%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 4.76%
Dyspnea (difficult or laboured breathing): 1 person, 4.76%

* Approximation only. Some reports may have incomplete information.

Do you take Questran and have Interstitial lung disease?

- Check whether Interstitial lung disease is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Questran:

Questran (4,490 reports)

Browse all side effects of Questran:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Interstitial lung disease:

Interstitial lung disease (1,500 drugs)

Browse all the conditions that are associated with Interstitial lung disease:

Interstitial lung disease (1,839 conditions)

Related publications that referenced our studies

Thangakunam B, Christopher DJ, Mathews V, Srivastava A, "Mesenchymal stromal stem cell therapy in advanced interstitial lung disease-Anaphylaxis and short-term follow-up", Lung India: official organ of Indian Chest Society, 2015 Jan .
Kato, M., Oiso, N., Nozaki, Y., Inoue, A., Hosono, Y., Funauchi, M., ... & Kawada, A., "Antitumor necrosis factor alpha inhibitor‐induced dermatomyositis and interstitial lung disease with anti‐PL 12 autoantibody: Signs of antisynthetase syndrome", The Journal of dermatology, 2012 Jan .
Thangakunam B, Christopher DJ, Mathews V, Srivastava A, "Mesenchymal stromal stem cell therapy in advanced interstitial lung disease-Anaphylaxis and short-term follow-up", Lung India: official organ of Indian Chest Society, 2015 Jan .
Kato, M., Oiso, N., Nozaki, Y., Inoue, A., Hosono, Y., Funauchi, M., ... & Kawada, A., "Antitumor necrosis factor alpha inhibitor‐induced dermatomyositis and interstitial lung disease with anti‐PL 12 autoantibody: Signs of antisynthetase syndrome", The Journal of dermatology, 2012 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on cholestyramine (the active ingredients of Questran) and Questran (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.